Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (NASDAQ: EXEL), Ionis Pharmaceuticals (NASDAQ: IONS) and Zogenix (NASDAQ: ZGNX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exelixis (EXELResearch Report), Ionis Pharmaceuticals (IONSResearch Report) and Zogenix (ZGNXResearch Report).

Exelixis (EXEL)

In a report released yesterday, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis. The company’s shares closed last Monday at $19.07.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 20.3% and a 66.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Nektar Therapeutics, and Seattle Genetics.

Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $23.71, which is a 28.0% upside from current levels. In a report issued on January 24, Cowen & Co. also maintained a Buy rating on the stock with a $23.00 price target.

See today’s analyst top recommended stocks >>

Ionis Pharmaceuticals (IONS)

William Blair analyst Myles Minter maintained a Hold rating on Ionis Pharmaceuticals yesterday. The company’s shares closed last Monday at $60.42.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 136.9% and a 100.0% success rate. Minter covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Axsome Therapeutics, and Karuna Therapeutics.

Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $75.60.

Zogenix (ZGNX)

William Blair analyst Tim Lugo maintained a Buy rating on Zogenix today. The company’s shares closed last Monday at $32.86, close to its 52-week low of $32.65.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 11.8% and a 46.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $56.75 average price target, representing a 48.6% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $64.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.